Clinical trial
A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460)
NCT02909452 is registered in ClinicalTrials.gov with Syndax Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460)
- Lead sponsor
- Syndax Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 20, 2016
- Completion date
- February 9, 2021
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast diseases, bronchial neoplasms, carcinoma, non-small-cell lung, digestive system neoplasms, endocrine gland neoplasms, lung diseases, lung neoplasms, neoplasms, neoplasms by histologic type, neoplasms, glandular and epithelial, renal neoplasm, respiratory tract neoplasms, solid tumors, thoracic neoplasms